CDMO and API manufacturer Seqens has announced a “multi-million dollar” investment in its R&D laboratory in Devens, Massachusetts, which is due to be completed in October. The firm said that this will ensure that the new facility can operate at the highest standards of safety and quality.
CDMO Seqens has confirmed that its planned change of ownership has been completed, with SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, becoming the majority shareholder.
SK Capital Partners has announced that it, Eurazeo and other shareholders in Seqens have entered a formal agreement for it to acquire Seqens. This follows a period of exclusive negotiations and the agreement of the employee representative body. This remains subject to regulatory approval. S
Eurazeo has announced that it has entered into exclusive discussions to sell its stake in French-based CDMO Seqens to funds advised by SK Capital Partners and its existing French shareholders, Mérieux Equity Partners.
Seqens commented that SK Capital’s involvement could enhance its position in the production of APIs, pharmaceutical intermediates and speciality ingredients. SK has already owned API manufacturer Wavelength Pharmaceuticals since 2017.
Seqens has revealed that it is commissioning a new plant at its site, which was formerly part of Chemoxy, in Billingham, north-east England. This will make diols such as 1,2-hexanediol, 2-ethylhexylglycerin and caprylyl glycol for use in cosmetic ingredients and hand sanitisers.
The investment cost over £10 million and commercial production should start in June. It is expected to create 15 new jobs, plus further work in the global distribution chain. The site has already been producing hand sanitiser since May 2020.
CDMO Seqens is to partner with its French compatriot Rondol, a specialist in drug dosage extrusion technologies via hot melt extrusion. Their stated aim is “to accelerate the development and commercialisation of extruded dosage forms with improved bioavailability, reduced side effects and optimised manufacturing costs”. Seqens will implement the technique within its Seqens’Lab at Porcheville.
Seqens will produce the first volumes of an aromatic diamine monomer by means of flow chemistry in its dedicated workshop at SeqensLab in Porcheville, France (pictured), by the end of 2021. This follows a successful first pilot trial in 2020.